flt201
Gaucher Disease Type 1
Spur Therapeuticsgene_therapyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Gaucher Disease Type 1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cerezyme Sanofi | Phase 4 | A |
Velaglucerase Alfa Baylor Research Institute | Phase 4 | BB |
Miglustat Actelion | Phase 3 | BB |
Eliglustat Sanofi | Phase 3 | BB |
Cerezyme Sanofi | Phase 3 | BB |
View all 13 →
Same molecule, other indications
flt201 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →